Merrimack Pharmaceuticals, Inc. (MACK) Financials
Stock symbol MACK is outdated, potentially delisted? Maybe it is available on other exchange?
MACK Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Dec. 31, 2023 | 19.2 million | 441000 |
| Sept. 30, 2023 | 19.3 million | 493000 |
| June 30, 2023 | 19.4 million | 411000 |
| March 31, 2023 | 19.6 million | 463000 |
MACK Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Dec. 31, 2023 | -295000 | 48000 |
| Sept. 30, 2023 | -203000 | 48000 |
| June 30, 2023 | -668000 | 47000 |
| March 31, 2023 | -356000 | 17000 |
MACK Net Income
No data available :(
MACK Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Dec. 31, 2023 | 18.9 million | - | - |
| Sept. 30, 2023 | 18.9 million | - | - |
| June 30, 2023 | 19.0 million | - | - |
| March 31, 2023 | 19.4 million | - | - |
MACK Shares Outstanding
MACK Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Dec. 31, 2023 | - | - | 490000 | - |
| Sept. 30, 2023 | - | - | 531000 | - |
| June 30, 2023 | - | - | 569000 | - |
| March 31, 2023 | - | 139000 | 586000 | - |
MACK Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Dec. 31, 2023 | - | - |
| Sept. 30, 2023 | - | - |
| June 30, 2023 | - | - |
| March 31, 2023 | - | - |
MACK
Price: $15.14
52 week price:
Earnings Per Share: -0.08 USD
P/E Ratio: -138
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 32078
Ebitda: -5.0 millionMarket Capitalization: 218.4 million